JP2010529010A - 植物抽出物及びその治療的使用 - Google Patents
植物抽出物及びその治療的使用 Download PDFInfo
- Publication number
- JP2010529010A JP2010529010A JP2010509896A JP2010509896A JP2010529010A JP 2010529010 A JP2010529010 A JP 2010529010A JP 2010509896 A JP2010509896 A JP 2010509896A JP 2010509896 A JP2010509896 A JP 2010509896A JP 2010529010 A JP2010529010 A JP 2010529010A
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- composition
- disease
- oil
- black cumin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000001225 therapeutic effect Effects 0.000 title description 8
- 239000000419 plant extract Substances 0.000 title description 2
- 239000000203 mixture Substances 0.000 claims abstract description 83
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 16
- 230000002062 proliferating effect Effects 0.000 claims abstract description 13
- 239000006286 aqueous extract Substances 0.000 claims abstract description 11
- 229940070641 chamomile flowers Drugs 0.000 claims abstract description 10
- 244000090896 Nigella sativa Species 0.000 claims description 34
- 235000016698 Nigella sativa Nutrition 0.000 claims description 34
- 239000003921 oil Substances 0.000 claims description 26
- 102000004889 Interleukin-6 Human genes 0.000 claims description 23
- 108090001005 Interleukin-6 Proteins 0.000 claims description 23
- 229940100601 interleukin-6 Drugs 0.000 claims description 23
- 239000000341 volatile oil Substances 0.000 claims description 23
- 244000042664 Matricaria chamomilla Species 0.000 claims description 21
- 235000007232 Matricaria chamomilla Nutrition 0.000 claims description 21
- 150000002617 leukotrienes Chemical class 0.000 claims description 19
- 201000010099 disease Diseases 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 235000007866 Chamaemelum nobile Nutrition 0.000 claims description 10
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- -1 phenol compound Chemical class 0.000 claims description 10
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 9
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 claims description 9
- 206010060862 Prostate cancer Diseases 0.000 claims description 8
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 8
- 239000002158 endotoxin Substances 0.000 claims description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 6
- 235000001671 coumarin Nutrition 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 6
- 208000005017 glioblastoma Diseases 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 229940069328 povidone Drugs 0.000 claims description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 6
- 235000011152 sodium sulphate Nutrition 0.000 claims description 6
- 238000001256 steam distillation Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 3
- 229960000956 coumarin Drugs 0.000 claims description 3
- 150000004775 coumarins Chemical class 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- 230000002829 reductive effect Effects 0.000 claims description 3
- GXGJIOMUZAGVEH-UHFFFAOYSA-N Chamazulene Chemical compound CCC1=CC=C(C)C2=CC=C(C)C2=C1 GXGJIOMUZAGVEH-UHFFFAOYSA-N 0.000 claims description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 2
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims description 2
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims description 2
- 229960004308 acetylcysteine Drugs 0.000 claims description 2
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims description 2
- PMRJYBALQVLLSJ-UHFFFAOYSA-N chamazulene Natural products CCC1=CC2=C(C)CCC2=CC=C1 PMRJYBALQVLLSJ-UHFFFAOYSA-N 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 239000007972 injectable composition Substances 0.000 claims description 2
- 239000012299 nitrogen atmosphere Substances 0.000 claims description 2
- 150000002989 phenols Chemical class 0.000 claims description 2
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 claims 1
- 230000005784 autoimmunity Effects 0.000 claims 1
- 229930003935 flavonoid Natural products 0.000 claims 1
- 150000002215 flavonoids Chemical class 0.000 claims 1
- 235000017173 flavonoids Nutrition 0.000 claims 1
- 239000012535 impurity Substances 0.000 claims 1
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- 239000011148 porous material Substances 0.000 claims 1
- 238000000108 ultra-filtration Methods 0.000 claims 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 41
- 235000019198 oils Nutrition 0.000 description 20
- 230000000694 effects Effects 0.000 description 15
- 238000003556 assay Methods 0.000 description 14
- 230000005764 inhibitory process Effects 0.000 description 14
- 230000006820 DNA synthesis Effects 0.000 description 12
- 239000001711 nigella sativa Substances 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 9
- 102100022364 Polyunsaturated fatty acid 5-lipoxygenase Human genes 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 101000620009 Homo sapiens Polyunsaturated fatty acid 5-lipoxygenase Proteins 0.000 description 7
- 239000010628 chamomile oil Substances 0.000 description 7
- 235000019480 chamomile oil Nutrition 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 239000003765 sweetening agent Substances 0.000 description 6
- 235000015112 vegetable and seed oil Nutrition 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000007859 condensation product Substances 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 235000003599 food sweetener Nutrition 0.000 description 5
- 210000003714 granulocyte Anatomy 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 101001074035 Homo sapiens Zinc finger protein GLI2 Proteins 0.000 description 4
- 235000007413 Nigella arvensis Nutrition 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 102100035558 Zinc finger protein GLI2 Human genes 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 244000215068 Acacia senegal Species 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229920000084 Gum arabic Polymers 0.000 description 3
- 235000017945 Matricaria Nutrition 0.000 description 3
- 235000004429 Matricaria chamomilla var recutita Nutrition 0.000 description 3
- 244000067946 Matricaria chamomilla var. recutita Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 235000010489 acacia gum Nutrition 0.000 description 3
- 239000000205 acacia gum Substances 0.000 description 3
- 235000020221 chamomile extract Nutrition 0.000 description 3
- 229960000913 crospovidone Drugs 0.000 description 3
- 239000001546 cuminum cyminum l. fruit oil Substances 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 3
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 229940104230 thymidine Drugs 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 235000003911 Arachis Nutrition 0.000 description 2
- 244000105624 Arachis hypogaea Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 229940119217 chamomile extract Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- VNYSSYRCGWBHLG-AMOLWHMGSA-M leukotriene B4(1-) Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC([O-])=O VNYSSYRCGWBHLG-AMOLWHMGSA-M 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 229940042880 natural phospholipid Drugs 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 description 2
- 239000001593 sorbitan monooleate Substances 0.000 description 2
- 229940035049 sorbitan monooleate Drugs 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 238000003026 viability measurement method Methods 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 1
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 1
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- HIYAVKIYRIFSCZ-CYEMHPAKSA-N 5-(methylamino)-2-[[(2S,3R,5R,6S,8R,9R)-3,5,9-trimethyl-2-[(2S)-1-oxo-1-(1H-pyrrol-2-yl)propan-2-yl]-1,7-dioxaspiro[5.5]undecan-8-yl]methyl]-1,3-benzoxazole-4-carboxylic acid Chemical compound O=C([C@@H](C)[C@H]1O[C@@]2([C@@H](C[C@H]1C)C)O[C@@H]([C@@H](CC2)C)CC=1OC2=CC=C(C(=C2N=1)C(O)=O)NC)C1=CC=CN1 HIYAVKIYRIFSCZ-CYEMHPAKSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101100268670 Caenorhabditis elegans acc-3 gene Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 240000004760 Pimpinella anisum Species 0.000 description 1
- 235000012550 Pimpinella anisum Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QTENRWWVYAAPBI-YZTFXSNBSA-N Streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O QTENRWWVYAAPBI-YZTFXSNBSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Natural products O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229940036350 bisabolol Drugs 0.000 description 1
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000003710 calcium ionophore Substances 0.000 description 1
- HIYAVKIYRIFSCZ-UHFFFAOYSA-N calcium ionophore A23187 Natural products N=1C2=C(C(O)=O)C(NC)=CC=C2OC=1CC(C(CC1)C)OC1(C(CC1C)C)OC1C(C)C(=O)C1=CC=CN1 HIYAVKIYRIFSCZ-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 1
- 229960001348 estriol Drugs 0.000 description 1
- CJAONIOAQZUHPN-KKLWWLSJSA-N ethyl 12-[[2-[(2r,3r)-3-[2-[(12-ethoxy-12-oxododecyl)-methylamino]-2-oxoethoxy]butan-2-yl]oxyacetyl]-methylamino]dodecanoate Chemical compound CCOC(=O)CCCCCCCCCCCN(C)C(=O)CO[C@H](C)[C@@H](C)OCC(=O)N(C)CCCCCCCCCCCC(=O)OCC CJAONIOAQZUHPN-KKLWWLSJSA-N 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 229940043351 ethyl-p-hydroxybenzoate Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960004719 nandrolone Drugs 0.000 description 1
- NPAGDVCDWIYMMC-IZPLOLCNSA-N nandrolone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 NPAGDVCDWIYMMC-IZPLOLCNSA-N 0.000 description 1
- 239000007908 nanoemulsion Substances 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 238000000424 optical density measurement Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 231100000747 viability assay Toxicity 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
【選択図】なし
Description
(1) 増殖性及び/又は炎症性疾患の治療のための、カモミールの花の水性抽出物を含む組成物;
(2) 水性抽出物が揮発油であり、揮発油は、好ましくは減圧下で、カモミールの花の水蒸気蒸留を含む抽出工程によって得られる、(1)に記載の組成物;
(3) カモミールの花がフローレス・テュビフォルミス(Flores tubiformis)である、(1)又は(2)に記載の組成物;
(4) (2)又は(3)に記載の組成物であって、水蒸気蒸留が窒素雰囲気下で実施され、工程がさらに、
(i) 組成物を、クマリンと複合体を形成する架橋型ポビドンと接触させる工程;
(ii) 工程(i)で形成された架橋型ポビドンとクマリンとの複合体を除去する工程;
(iii) 工程(ii)から得られた組成物を無水硫酸ナトリウムと接触させることにより水残留分を除去する工程;及び
(iv) 工程(iii)で得られた組成物から硫酸ナトリウムを分離する工程
を含む、組成物;
(5) (1)〜(4)のいずれかに記載の組成物であって、組成物がブラッククミン油をさらに含む、組成物;
(6) (5)に記載の組成物であって、ブラッククミン油が、
(i) ブラッククミン油を、フェノール化合物と複合体を形成する架橋型ポビドンと接触させる工程;
(ii) 工程(i)で形成されたクロスポビドンとフェノール化合物との複合体を除去する工程;
(iii) 工程(ii)から得られたブラッククミン油を無水硫酸ナトリウムと接触させることにより水残留分を除去する工程;及び
(iv) 工程(iii)で得られたブラッククミン油から硫酸ナトリウムを分離する工程
を含む精製工程によって得られる、精製ブラッククミン油である、組成物;
(7) (1)〜(6)のいずれかに記載の組成物であって、疾患が、好ましくはクローン病及び多発性硬化症からなる群から選択される、炎症性疾患であることを特徴とする組成物;
(8) (1)〜(6)のいずれかに記載の組成物であって、疾患が、好ましくは膠芽細胞腫、肺癌及び前立腺癌からなる群から選択される、癌であることを特徴とする組成物;
(9) (1)〜(7)のいずれかに記載の組成物であって、炎症性疾患が自己免疫症によって引き起こされ、好ましくはインターロイキン6によって誘発され、より好ましくはロイコトリエンによって誘発され、最も好ましくはインターロイキン6及び/又はロイコトリエンの存在に依存する、ことを特徴とする組成物;
(10) (1)〜(6)及び(8)のいずれかに記載の組成物であって、疾患が増殖性疾病によって引き起こされ、好ましくはインターロイキン6によって誘発され、より好ましくはロイコトリエンによって誘発され、最も好ましくはインターロイキン6及び/又はロイコトリエンの存在に依存する、ことを特徴とする組成物;
(11) 増殖性及び/又は炎症性疾患の治療用薬剤の製造のための、(1)〜(6)のいずれかに規定された通りの組成物の使用;
(12) (11)に記載の使用であって、疾患が請求項(7)〜(10)のいずれかに規定された通りである、使用;
(13) (1)〜(6)のいずれかに規定された通りの組成物の有効量を、それを必要とするヒト又は動物患者に投与することを含む、増殖性及び/又は炎症性疾患の治療方法;並びに、
(14) 疾患が(7)〜(10)のいずれかに規定された通りである、(13)に記載の方法
に関する。
本発明は、好ましくは水蒸気蒸留によって得られる、カモミールの頭状花の水性抽出物を使用して得られたデータに基づいている。正確には、水性抽出物は、当業者にはPhEur 5.1に記載されたMatricariae aetheroleumとしても知られる、Matricaria recutita L.の頭状花の揮発成分より構成される。本発明は、さらに、ブラッククミン種子油とカモミールの頭状花の揮発油との組み合わせを使用して得られたデータに基づいている。
サンプルは、PMAで予め分化した細胞(ヒトTHP-1)と共に、37℃で30分間、プレインキュベートした(0.125x106細胞/ウェル)。LPS(1μg/ml)で反応を開始し、37℃で24時間インキュベートした。LPS刺激をしないアッセイ混合物を用いて、陰性対照t(0)を実施した[参照1]。
実施例1の結果を図1に示す。
異なる濃度のNICHA下で、ロイコトリエン放出に対する2つのヒト細胞株(顆粒球)の応答を調べた。各試験は、ニゲラ油、カモミール油及び2つの油の組み合わせを用いて実施した。
ヒトHL-60細胞(骨髄性白血病、DSMZ No ACC 3)を、5%CO2を含む加湿雰囲気中、37℃で保持し、10%ウシ胎仔血清及び1%(v/v)ペニシリン/ストレプトマイシン溶液を補足した完全RPMI1640培地中で培養した。細胞をDMSO(1.2% v/v)で6〜8日間分化させた。ベネット(Bennet)らによって記載された通り、5-LOX活性のアッセイを実施した[参照2]。簡単に説明すると、分化した細胞を採取し、Ca2+(1mM)及びグルコース(1mM)を含有するPBS中に懸濁させ、96穴マイクロタイタープレートに分配した(1x106細胞/ウェル)。
細胞機能/ミトコンドリア:ヒト肝細胞(Hep G2)、ヒト顆粒球(分化型HL60)、ヒト単球(THP-1)及びヒトマクロファージ(分化型THP-1)について、テトラゾリウム塩WST-1キット(バイオビジョン(Biovision)、K301-500、米国カリフォルニア州)を用いて、代謝活性の減少[参照4]を試験した。細胞を抽出物と共に24時間プレインキュベートした。
実施例2の結果を、図2及び3に示す。
異なる濃度のNICHA下で、膠芽腫細胞及び前立腺癌細胞の増殖応答を調べた。各試験は、ニゲラ油、カモミール油及び2つの油の組み合わせを用いて行った。
3H-チミジン取り込み:トリプシン処理により、DU145及びU-87MG細胞を採取し、96穴プレートに10'000細胞/ウェルで播種した。細胞を所要の濃度のサンプルと共に37℃、5%CO2で24時間及び/又は48時間インキュベートした。細胞を3H-チミジン(1μCi/ml)(パーキン・エルマー(Perkin Elmer))で24時間パルスした。その後、細胞をPBSで洗浄し、メタノールで5分間の固定を2回行った。タンパク質は0.3N TCAで沈殿させた。洗浄工程の後、150μlの0.3N NaOHを15分間で加え、細胞を溶解した。バックグラウンド対照は、細胞を含まないサンプルで測定した。
前立腺癌細胞(DU145)におけるDNA合成に対するNICHAの効果の結果を、図4A〜4Dに示す。
DNA合成に対する対照化合物のIC50値は以下の通りである。
U-87MG細胞におけるDNA合成に対するNICHAの効果(48時間インキュベート)の結果を、図5A〜5Cに示す。
U-87MG細胞を用いたDNA合成に対する対照化合物のIC50値は以下の通りである。
分化したヒト顆粒球細胞株HL 60(ヒト急性骨髄性白血病)において、カモミール(マトリカリア・レクティカ(Matricaria recutita): VIP_Matr07_78)の精油およびブラッククミン(ニゲラ・サティバ(Nigella sativa): VIP_Nig07_8)の種子油の、ロイコトリエン合成を阻害する潜在力を調べた。ニゲラ・サティバ(Nigella sativa)種子油は、5-Lox活性の優れた阻害を示し、IC 50値は3.02ug/mlであった(実施例2、図2d)。驚くべきことに、HL60顆粒球細胞株において、2つの化合物の混合物がロイコトリエンの合成を相加以上に阻害した。期待されたIC 50は0.76ug/mlであったが、結果はIC50が0.53ug/mlであった(実施例2、図2e)。2つの化合物の組み合わせが単一成分の活性を促進すると結論付けることができる。
Claims (27)
- 増殖性及び/又は炎症性疾患の治療のための、カモミールの花の水性抽出物を含む組成物。
- カモミールの花がフローレス・テュビフォルミス(Flores tubiformis)である、請求項1に記載の組成物。
- 水性抽出物が、好ましくは減圧下で、カモミールの花の水蒸気蒸留を含む抽出工程によって得られる揮発油である、請求項1又は請求項2に記載の組成物。
- 水蒸気蒸留が窒素雰囲気下で実施され、かつ工程がさらに、
(i) 組成物を、クマリンと複合体を形成する架橋型ポビドンと接触させる工程;
(ii) 工程(i)で得られた複合体を除去する工程;及び
(iii) 工程(ii)から得られた組成物を無水硫酸ナトリウムと接触させることにより脱水する工程;及び
(iv) 工程(iii)で得られた組成物から硫酸ナトリウムを分離する工程
を含む、請求項3に記載の組成物。 - 実質的に水を含有せず、好ましくは0.1%w/w未満の水を含有し、最も好ましくは0.01%w/w未満の水を含有する、請求項4に記載の組成物。
- 実質的にクマリンを含有せず、好ましくは、7-ヒドロキシクマリンとして計算して0.01%w/w未満のクマリンを含有し、最も好ましくは0.005%w/w未満のクマリンを含有する、請求項5に記載の組成物。
- カマズレンを5〜15%w/w、より好ましくは15〜25%w/w、最も好ましくは20〜30%w/wの量で含有する、請求項5又は請求項6に記載の組成物。
- ブラッククミン油をさらに含む、請求項1〜7のいずれかに記載の組成物。
- ブラッククミン油が、
(i) ブラッククミン油を、フェノール化合物と複合体を形成する架橋型ポビドンと接触させる工程;
(ii) 工程(i)で得られた複合体を除去する工程;及び
(iii) 工程(ii)から得られたブラッククミン油を無水硫酸ナトリウムと接触させることにより脱水する工程;及び
(iv) 工程(iii)で得られたブラッククミン油から硫酸ナトリウムを分離する工程
を含む精製工程によって得られる、精製ブラッククミン油である、請求項8に記載の組成物。 - 組成物が、好ましくは孔径が0.001〜0.02μm、より好ましくは0.001〜0.01μmのフィルターを用いた、限外濾過によって得られる、請求項1〜9のいずれかに記載の組成物。
- エンドトキシンを含まないか又は実質的に含まず、好ましくはエンドトキシンを100 EU/ml(欧州薬局方による、ml当りのエンドトキシンユニット)以下、より好ましくは50 EU/ml以下、さらにより好ましくは10 EU/ml以下の量で含有する、請求項1〜10のいずれかに記載の組成物。
- 分子量が10,000を超える物質を含有せず、より好ましくは分子量が1,000を超える物質を含有しない、請求項1〜11のいずれかに記載の組成物。
- クマリン、フラボノイド、カモミール及び/又はブラッククミンの典型的な不純物である他のフェノール化合物、及び残留水からなる群から選択される化合物を含有しないか又は実質的に含有しない、請求項1〜12のいずれかに記載の組成物。
- パルミチン酸アスコルビル及び/又はアセチルシステインをさらに含む、請求項1〜13のいずれかに記載の組成物。
- 好ましくは医薬品及び医薬品賦形剤からなる群から選択される、少なくとも1つの製剤助剤をさらに含む、請求項1〜14のいずれかに記載の組成物。
- 治療が組成物の注射又は吸入による、請求項1〜15のいずれかに記載の組成物。
- 疾患が、好ましくはクローン病及び多発性硬化症からなる群から選択される、炎症性疾患である、請求項1〜16のいずれかに記載の組成物。
- 疾患が、好ましくは膠芽細胞腫、肺癌及び前立腺癌からなる群から選択される、癌である、請求項1〜16のいずれかに記載の組成物。
- 炎症性疾患が自己免疫症によって引き起こされ、好ましくはインターロイキン6によって誘発され、より好ましくはロイコトリエンによって誘発され、最も好ましくはインターロイキン6及び/又はロイコトリエンの存在に依存する、請求項1〜17のいずれかに記載の組成物。
- 疾患が増殖性疾病によって引き起こされ、好ましくはインターロイキン6によって誘発され、より好ましくはロイコトリエンによって誘発され、最も好ましくはインターロイキン6及び/又はロイコトリエンの存在に依存する、請求項1〜16及び18のいずれかに記載の組成物。
- 増殖性及び/又は炎症性疾患の治療用薬剤の製造のための、請求項1〜15のいずれかに規定された通りの組成物の使用。
- 治療が請求項16に規定された通りである、請求項21に記載の使用。
- 疾患が請求項17〜20のいずれかに規定された通りである、請求項21又は22に記載の使用。
- 請求項1〜15のいずれかに規定された通りの組成物の有効量を、それを必要とするヒト又は動物患者に投与することを含む、増殖性及び/又は炎症性疾患の治療方法。
- 投与が組成物の注射及び/又は吸入による、請求項24に記載の方法。
- 組成物が注射可能な組成物である、請求項25に記載の方法。
- 疾患が請求項17〜20のいずれかに規定された通りである、請求項24〜26のいずれかに記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0710536.4 | 2007-06-01 | ||
GBGB0710536.4A GB0710536D0 (en) | 2007-06-01 | 2007-06-01 | Plant extract and its therapeutic use |
PCT/GB2008/001849 WO2008146009A1 (en) | 2007-06-01 | 2008-06-02 | Plant extract and its therapeutic use |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010529010A true JP2010529010A (ja) | 2010-08-26 |
JP5478486B2 JP5478486B2 (ja) | 2014-04-23 |
Family
ID=38289721
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010509896A Active JP5478486B2 (ja) | 2007-06-01 | 2008-06-02 | 植物抽出物及びその治療的使用 |
Country Status (17)
Country | Link |
---|---|
US (2) | US8591966B2 (ja) |
EP (1) | EP2150263B1 (ja) |
JP (1) | JP5478486B2 (ja) |
KR (1) | KR101202913B1 (ja) |
CN (1) | CN101687001A (ja) |
AR (1) | AR066822A1 (ja) |
AT (1) | ATE544458T1 (ja) |
AU (1) | AU2008256536B2 (ja) |
BR (1) | BRPI0812028A2 (ja) |
CA (1) | CA2688410C (ja) |
ES (1) | ES2378912T3 (ja) |
GB (1) | GB0710536D0 (ja) |
IL (1) | IL202440A (ja) |
RU (1) | RU2438692C2 (ja) |
TW (1) | TW200916111A (ja) |
WO (1) | WO2008146009A1 (ja) |
ZA (1) | ZA200907899B (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0808974D0 (en) * | 2008-05-16 | 2008-06-25 | Veritron Ltd | Plant extract and its therapeutic use |
MY162725A (en) * | 2008-12-04 | 2017-07-14 | Univ Putra Malaysia | Extractions of fixed oil and thymoquinone rich fractions (tqrf) |
EP2420228A1 (en) | 2010-08-05 | 2012-02-22 | Alpinia Laudanum Institute Of Phytopharmaceutical Sciences AG | Composition comprising retinol, a precursor or a reaction product of it and a plant extract from at least one chamomilla plant for the treatment of cancer |
AU2013209394A1 (en) * | 2012-01-20 | 2014-08-28 | Dennis Brown | Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem cells including glioblastoma multforme and medulloblastoma |
US9719970B2 (en) | 2012-11-30 | 2017-08-01 | Waters Technologies Corporation | Methods and apparatus for the analysis of vitamin D metabolites |
WO2015124321A1 (en) * | 2014-02-24 | 2015-08-27 | Alpinia Laudanum Institute Of Phytopharmaceutical Sciences Ag | Compositions for use in the treatment of mucositis and/or stomatitis |
US10409366B2 (en) * | 2014-04-28 | 2019-09-10 | Adobe Inc. | Method and apparatus for controlling display of digital content using eye movement |
US10409456B2 (en) * | 2015-06-09 | 2019-09-10 | Disney Enterprises, Inc. | Dynamically changing a 3D object into an interactive 3D menu |
CN108853264B (zh) * | 2017-05-12 | 2021-10-15 | 圣莲生物科技股份有限公司 | 预防或改善缺血性脑中风之中草药组合物 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6300370B1 (en) * | 1987-02-13 | 2001-10-09 | Asta Medica Aktiengesellschaft | Camomile oils having a high content of natural poly-ynes and process for their preparation |
JP2005519055A (ja) * | 2002-01-11 | 2005-06-30 | ラート・マティアス | ポリフェノール類を含む栄養医薬製剤および癌の治療におけるその使用方法(関連出願の説明)本願は、2002年1月11日に出願された米国仮特許出願第60/348,143号の、米国特許法第119条(e)に基づく利益を主張し、その内容は参照によりそのまま本明細書に組み込まれるものとする。 |
JP2006510592A (ja) * | 2002-09-11 | 2006-03-30 | エスケー ケミカルズ カンパニー リミテッド | スイカズラ(LonicerajaponicaThunb.)茎の活性成分の抽出および精製方法、その消炎鎮痛剤への用途 |
WO2007057651A1 (en) * | 2005-11-15 | 2007-05-24 | Veritron Limited | Purification and endotoxin-removal process |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9904777D0 (en) * | 1999-03-02 | 1999-04-28 | Nassief Nida A | Novel method, an asthma therapy that act on eosinophils and/or t-lymphocytes |
US20030180395A1 (en) * | 2000-07-26 | 2003-09-25 | Bernd Bueter | Plant extract |
US20030060454A1 (en) * | 2000-12-29 | 2003-03-27 | Osama Kandil | Total lipid fraction of Nigella sativa L. seeds |
ITMI20012142A1 (it) | 2001-10-17 | 2003-04-17 | Mario Baraldi | Composizioni farmaceutiche per uso topico contenenti estratti di erbemedicinali ad attivita' antilogistica e cicatrizzante |
US20050019323A1 (en) * | 2002-05-22 | 2005-01-27 | Protein Design Labs, Inc. | Treatment of Crohn's disease or psoriasis using anti-interferon gamma antibodies |
GB0212405D0 (en) | 2002-05-29 | 2002-07-10 | Insignion Holdings Ltd | Composition and its therapeutic use |
WO2005070440A1 (en) | 2004-01-24 | 2005-08-04 | Eman Gaber Haggag | Herbal formula for the treatment of allergic asthma ( chronic bronchial asthma) |
US7090879B2 (en) * | 2004-03-18 | 2006-08-15 | Abbott Laboratories | Nutritional formula containing select carotenoid combinations |
GB0501655D0 (en) * | 2005-01-26 | 2005-03-02 | Veritron Ltd | Therapeutic use |
DE202006019183U1 (de) * | 2006-12-15 | 2007-04-19 | Franz, Tanja | Sanddorn-Hautpflegeöl |
-
2007
- 2007-06-01 GB GBGB0710536.4A patent/GB0710536D0/en not_active Ceased
-
2008
- 2008-06-02 BR BRPI0812028A patent/BRPI0812028A2/pt not_active IP Right Cessation
- 2008-06-02 KR KR1020097024924A patent/KR101202913B1/ko not_active IP Right Cessation
- 2008-06-02 CN CN200880018227A patent/CN101687001A/zh active Pending
- 2008-06-02 AR ARP080102327A patent/AR066822A1/es unknown
- 2008-06-02 AU AU2008256536A patent/AU2008256536B2/en not_active Ceased
- 2008-06-02 EP EP08750733A patent/EP2150263B1/en active Active
- 2008-06-02 RU RU2009148321/15A patent/RU2438692C2/ru not_active IP Right Cessation
- 2008-06-02 AT AT08750733T patent/ATE544458T1/de active
- 2008-06-02 TW TW097120549A patent/TW200916111A/zh unknown
- 2008-06-02 WO PCT/GB2008/001849 patent/WO2008146009A1/en active Application Filing
- 2008-06-02 ES ES08750733T patent/ES2378912T3/es active Active
- 2008-06-02 CA CA2688410A patent/CA2688410C/en not_active Expired - Fee Related
- 2008-06-02 JP JP2010509896A patent/JP5478486B2/ja active Active
- 2008-06-02 US US12/602,272 patent/US8591966B2/en active Active
-
2009
- 2009-11-11 ZA ZA200907899A patent/ZA200907899B/xx unknown
- 2009-12-01 IL IL202440A patent/IL202440A/en not_active IP Right Cessation
-
2013
- 2013-09-25 US US14/036,608 patent/US20140023736A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6300370B1 (en) * | 1987-02-13 | 2001-10-09 | Asta Medica Aktiengesellschaft | Camomile oils having a high content of natural poly-ynes and process for their preparation |
JP2005519055A (ja) * | 2002-01-11 | 2005-06-30 | ラート・マティアス | ポリフェノール類を含む栄養医薬製剤および癌の治療におけるその使用方法(関連出願の説明)本願は、2002年1月11日に出願された米国仮特許出願第60/348,143号の、米国特許法第119条(e)に基づく利益を主張し、その内容は参照によりそのまま本明細書に組み込まれるものとする。 |
JP2006510592A (ja) * | 2002-09-11 | 2006-03-30 | エスケー ケミカルズ カンパニー リミテッド | スイカズラ(LonicerajaponicaThunb.)茎の活性成分の抽出および精製方法、その消炎鎮痛剤への用途 |
WO2007057651A1 (en) * | 2005-11-15 | 2007-05-24 | Veritron Limited | Purification and endotoxin-removal process |
Non-Patent Citations (3)
Title |
---|
JPN6012047070; 'Essential oil composition of Matricaria recutita L. from the lower region of the Himalayas' Flavour Fragr J Vol.21, No.2, 2006, p.274-276 * |
JPN6012047071; HOUGHTON,P.J. et al: 'Fixed Oil of Nigella sativa and Derived Thymoquinone Inhibit Eicosanoid Generation in Leukocytes and' Planta Med Vol.61, No.1, 1995, p.33-36 * |
JPN6012047072; HAJHASHEMI VALIOLLAH ET AL: 'Black cumin seed essential oil, as a potent analgesic and antiinflammatory drug' PHYTOTHERAPY RESEARCH vol. 18, no. 3, 200403, pages 195-199 * |
Also Published As
Publication number | Publication date |
---|---|
US20140023736A1 (en) | 2014-01-23 |
TW200916111A (en) | 2009-04-16 |
JP5478486B2 (ja) | 2014-04-23 |
EP2150263A1 (en) | 2010-02-10 |
BRPI0812028A2 (pt) | 2016-10-18 |
AR066822A1 (es) | 2009-09-16 |
IL202440A0 (en) | 2010-06-30 |
US8591966B2 (en) | 2013-11-26 |
ZA200907899B (en) | 2010-07-28 |
RU2009148321A (ru) | 2011-07-20 |
CN101687001A (zh) | 2010-03-31 |
CA2688410A1 (en) | 2008-12-04 |
AU2008256536B2 (en) | 2011-04-21 |
CA2688410C (en) | 2014-03-18 |
GB0710536D0 (en) | 2007-07-11 |
KR101202913B1 (ko) | 2012-11-19 |
WO2008146009A1 (en) | 2008-12-04 |
EP2150263B1 (en) | 2012-02-08 |
ATE544458T1 (de) | 2012-02-15 |
KR20100028540A (ko) | 2010-03-12 |
IL202440A (en) | 2013-10-31 |
AU2008256536A1 (en) | 2008-12-04 |
ES2378912T3 (es) | 2012-04-19 |
US20100178368A1 (en) | 2010-07-15 |
RU2438692C2 (ru) | 2012-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5478486B2 (ja) | 植物抽出物及びその治療的使用 | |
US7807711B2 (en) | Medicinal acidic cannabinoids | |
TWI501772B (zh) | 具抗關節炎活性的到手香精萃物 | |
JP5331962B2 (ja) | 炎症性疾患のための薬草組成物 | |
JP2011502995A (ja) | アンドログラフィス・パニキュラータ抽出物 | |
BR112015005942B1 (pt) | composição compreendendo extratos de cynara, coffea spp. e olea europaea, seu uso e composição farmacêutica | |
TWI320714B (en) | Plant extracts for the treatment of rheumatoid arthritis | |
JP5267885B2 (ja) | 絡石藤とイチヤクソウの混合抽出物を含有する炎症性疾患の予防及び/又は治療用医薬組成物 | |
KR101332824B1 (ko) | 민대극 추출물을 포함하는 관절염 예방 및 치료용 조성물 | |
KR101647506B1 (ko) | 황련 추출물의 독성 저감화 방법, 이로부터 제조된 독성이 저감화된 생약추출물, 및 그 생약추출물을 함유하는 호흡기 질환 예방 또는 치료용 조성물 | |
EP2025340A1 (en) | Plant extracts for the treatment of rheumatoid arthritis | |
JP2010235524A (ja) | 花粉荷を含有する抗ヒスタミン剤 | |
JP2009132634A (ja) | 抗肥満剤 | |
WO2001039785A1 (fr) | Formulation contenant un extrait de feuille de cacahouete et son procede de preparation | |
AU2014330796B2 (en) | Extracts and compositions of Helichrysum odoratissimum for preventing and treating skin cancers | |
CN113474001A (zh) | 包含香蜂花叶提取物的馏分的药物组合物 | |
CN115737627A (zh) | α-倒捻子素在制备防治高血压及高血压肾病药物中的用途 | |
KR20070088984A (ko) | 독활 추출물을 함유하는 염증성 질환 및 치료에 유용한 약제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120911 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121210 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121217 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130111 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130611 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131009 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131024 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20131115 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140114 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140210 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5478486 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |